Madrigal Pharmaceuticals (MDGL) Is Down 13.4% After Pfizer MASH Deal And Wolfe Downgrade - What's Changed [Yahoo! Finance]
Madrigal Pharmaceuticals, Inc. (MDGL)
Last madrigal pharmaceuticals, inc. earnings: 2/26 06:50 am
Check Earnings Report
US:NASDAQ Investor Relations:
madrigalpharma.com
Company Research
Source: Yahoo! Finance
Morgan Healthcare Conference on January 9, 2026. At the same time, a downgrade from Wolfe Research on valuation and competitive grounds has sharpened investor focus on the durability and breadth of Madrigal's MASH franchise. We'll now examine how Wolfe Research's valuation downgrade, alongside the Pfizer ervogastat license, may reshape Madrigal's investment narrative. Trump's oil boom is here - pipelines are primed to profit. Discover the 22 US stocks riding the wave To own Madrigal today, you need to believe Rezdiffra can anchor a durable MASH franchise while the company manages competition, reimbursement pressure and high ongoing losses. The Wolfe Research downgrade mainly highlights existing valuation and competition concerns, while the Pfizer ervogastat license does not materially change the near term focus on Rezdiffra execution and competitive risk. The new global license for Pfizer's ervogastat is the announcement that most directly connects to today's debate around M
Show less
Read more
Impact Snapshot
Event Time:
MDGL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MDGL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MDGL alerts
High impacting Madrigal Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
MDGL
News
- Madrigal Pharmaceuticals (NASDAQ:MDGL) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.MarketBeat
- Madrigal Pharmaceuticals (NASDAQ:MDGL) had its "buy" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..MarketBeat
- Madrigal Pharmaceuticals (NASDAQ:MDGL) had its "buy" rating reaffirmed by analysts at Cowen Inc.MarketBeat
- Assessing Madrigal Pharmaceuticals (MDGL) Valuation After Recent Share Price Volatility And Long Term Momentum [Yahoo! Finance]Yahoo! Finance
- Madrigal Expands its MASH Pipeline with Exclusive Global License Agreement for Ervogastat, a Phase 2 Oral DGAT-2 InhibitorGlobeNewswire
MDGL
Earnings
- 11/4/25 - Miss
MDGL
Sec Filings
- 12/12/25 - Form SCHEDULE
- 12/12/25 - Form SCHEDULE
- MDGL's page on the SEC website